"Chemoradiotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Treatment that combines chemotherapy with radiotherapy.
| Descriptor ID |
D059248
|
| MeSH Number(s) |
E02.186.079 E02.319.164 E02.815.160
|
| Concept/Terms |
Chemoradiotherapy- Chemoradiotherapy
- Chemoradiotherapies
- Radiochemotherapy
- Radiochemotherapies
Concurrent Chemoradiotherapy- Concurrent Chemoradiotherapy
- Chemoradiotherapies, Concurrent
- Chemoradiotherapy, Concurrent
- Concurrent Chemoradiotherapies
- Synchronous Chemoradiotherapy
- Chemoradiotherapies, Synchronous
- Chemoradiotherapy, Synchronous
- Synchronous Chemoradiotherapies
- Concurrent Radiochemotherapy
- Concurrent Radiochemotherapies
- Radiochemotherapies, Concurrent
- Radiochemotherapy, Concurrent
- Concomitant Chemoradiotherapy
- Chemoradiotherapies, Concomitant
- Chemoradiotherapy, Concomitant
- Concomitant Chemoradiotherapies
- Concomitant Radiochemotherapy
- Concomitant Radiochemotherapies
- Radiochemotherapies, Concomitant
- Radiochemotherapy, Concomitant
|
Below are MeSH descriptors whose meaning is more general than "Chemoradiotherapy".
Below are MeSH descriptors whose meaning is more specific than "Chemoradiotherapy".
This graph shows the total number of publications written about "Chemoradiotherapy" by people in this website by year, and whether "Chemoradiotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 3 | 5 |
| 2013 | 3 | 2 | 5 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 6 | 7 |
| 2016 | 3 | 3 | 6 |
| 2017 | 6 | 4 | 10 |
| 2018 | 1 | 5 | 6 |
| 2019 | 2 | 1 | 3 |
| 2020 | 2 | 4 | 6 |
| 2021 | 3 | 3 | 6 |
| 2022 | 0 | 6 | 6 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemoradiotherapy" by people in Profiles.
-
Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Patients with Cervical Cancer Undergoing Definitive Chemoradiation. Clin Cancer Res. 2025 Feb 17; 31(4):697-706.
-
Phase II Trial of Induction Chemotherapy for Advanced Sinonasal Squamous Cell Carcinoma. Clin Cancer Res. 2025 Jan 17; 31(2):258-265.
-
Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline. J Clin Oncol. 2025 Feb 10; 43(5):605-615.
-
Association of the time of day of chemoradiotherapy and durvalumab with tumor control in lung cancer. Radiother Oncol. 2025 Feb; 203:110658.
-
Can we safely de-escalate HPV+ oropharyngeal cancers? - A review of current practices and novel approaches. Oral Oncol. 2024 Dec; 159:107089.
-
The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma. Neuro Oncol. 2024 Oct 03; 26(10):1912-1920.
-
Challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations: recommendations from NRG Oncology, the American Society for Radiation Oncology (ASTRO), the American College of Radiology (ACR), the Sarah Cannon Research Institute, and the American College of Radiation Oncology (ACRO). Lancet Oncol. 2024 Oct; 25(10):e489-e500.
-
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC. J Thorac Oncol. 2025 Jan; 20(1):109-118.
-
Phase 1 Trial of Total Neoadjuvant Therapy With Short-Course Chemoradiotherapy Followed by Chemotherapy for Patients With Potentially Resectable Gastric Cancer. Int J Radiat Oncol Biol Phys. 2025 Feb 01; 121(2):423-431.
-
The Impact of MRI-Based Advanced Neuroimaging on Neurooncologists' Clinical Decision-Making in Patients With Posttreatment High-Grade Glioma: A Prospective Survey-Based Study. AJR Am J Roentgenol. 2024 Oct; 223(4):e2431595.